“NHSBT strategic vision meeting” Dr. Les Russell - October 2013 Tel +44 (0)1865 784156 Confidential to OrganOx.

Slides:



Advertisements
Similar presentations
Energy Efficiency Facility - Outline and Status - Dr. Claudia Loy Team Leader Energy, Environment, Agriculture and Transport Europe Division.
Advertisements

Toward a strategy to use more organs and distribute them to those in need Jean Emond New York.
Implementation of new technologies Dr Keith Cooper Southampton Health Technology Assessments Centre University of Southampton.
Towards Action Planning Linda Story Air Noise and Nuisance Team.
ORGAN TRANSPLANTATION LOGISTICS CASE FOR TURKEY By Pelin Cay. Academic Advisor: Assoc. Prof. Bahar Y. Kara 6/29/2012.
Donation After Cardiac Death May 26, 2010 Margie Whittaker, RN MSN.
Organ Donation Past, Present and Future Donation after Brain-Stem Death DBD Dr Ranjit Dulai Dr Dale Gardiner Dr Gerlinde Mandersloot 26 th June 2013.
Organ Donation and Transplantation Strategic Performance Update Sally Johnson 26 March 2015.
Organ Donation & Transplantation in Ireland – Changing times Aileen Counihan Transplant Co-ordinator Beaumont Hospital Beaumont Hospital.
Summary of the 2012 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2014.
A MULTIDISCIPLINARY ORGAN DONOR COUNCIL AND PERFORMANCE IMPROVEMENT INITIATIVE CAN HELP SAVE LIVES 2010 ONELEGACY CELEBRATING OUR PARTNERS May 26, 2010.
Horizon Scanning on organ perfusion
A single commissioning model for the organ donation and transplantation pathway – what are the pros and cons? Keith Rigg.
Harefield DCD heart transplant programme
Specialised Commissioning of Kidney Transplantation Keith Rigg Chair, Renal Transplant CRG.
 Allows a new type of organ transplantation › Living organ transplant  Maintains organs in warn functioning state outside of the body › Hearts beat.
Organ Donation in DCD: 10 Year Experience at the University of Michigan A Rojas-Pena, MD; L Sall, BS; K. Koch, BS; E Cooley, RN; M Gravel, RN; R Bartlett,
Keystone – Gift of Life Conference Call August 20, 2008 Update: Transplant Growth & Management Collaborative.
Breathing Lung- What can it do for lung numbers? Region 7 Education Meeting 2/13/14 Dr. Gail Frankle DHN, RN, CPTC Sr. Director Transplant Services, University.
November 12, 2014 St. Louis, Missouri OPTN Strategic Planning Feedback Board of Directors.
Comparison of HTK and UW in Abdominal Transplantation Dr. Richard S. Mangus, MD MS Indiana University, School of Medicine.
HEART DISEASE SBI 3C: DECEMBER HEART ATTACK:  Blood flow to a section of the heart is blocked  If oxygen cannot get through the muscle starts.
The Journey of Blood. Blood- the life source Slide 1: Blood is a scarce and vital national resource which cannot be synthesized. About 80 million unit.
DCD Approach Process: Maximizing the Gift Jamie Kothapalli, RN BSN Wisconsin Donor Network.
Ex Vivo Lung Perfusion with Adenosine A2A Receptor Agonist Decreases Ischemia-Reperfusion Injury in Donation after Cardiac Death CE Wagner, NH Pope, EJ.
2013 Data.  Overall waiting list additions increased for second year in a row  Most significant growth for kidney waiting list since “flattening” began.
Our Commitment to Patients and Transplant Recipients Dr. Butchi Paidipaity, MD.
Machine perfusion- Evaluation criteria HMPNRPNMP Better outcome ?++? Prediction of functionlimited++ Expansion of organ pool-++++? Organ reconditioning?Potential.
Liver and Intestinal Organ Transplantation Committee Update Report David Mulligan, MD, Chair OPTN/UNOS Board of Directors Meeting November 12-13, 2014.
Национальная процедура одобрения и регистрации проектов (программ) международной технической помощи (исключая представление информации об организации и.
Liver Transplantation
DEFINING A NEW TOOL FOR LIMITING DELAYED GRAFT FUNCTION FOR KIDNEYS IN COLD STORAGE: THE MACHINE PRESERVATION TO COLD ISCHEMIA TIME RATIO Michael J. Goldstein.
Achieving dryland women’s empowerment: environmental resilience and social transformation imperatives Presented by: John Morton V. Nelson, J. Morton, L.
Ante mortem interventions in DCD Dr Malcolm Watters Regional Clinical Lead for Organ Donation 1.
Summary of the 2013 ERA-EDTA Registry Annual Report Amsterdam, the Netherlands, 2015.
South Central Regional Collaborative Stretch Goal.
Can we improve deceased donor kidney utilisation? Chris Callaghan National Clinical Lead for Abdominal Organ Utilisation, NHSBT Consultant Transplant Surgeon,
1. Commitment to working with the community 2. Assessing our community 3. Identifying issues & priorities 4. Make recommendations 5. AVDHA considers recommendations.
Organ Donation Past, Present and Future Donation after Brain-Stem Death DBD Dr Farrel Igielman Dr Dale Gardiner Dr Gerlinde Mandersloot 4 th June 2013.
National Histopathology Service for Transplantation
Living donation review Renal Transplant Services Meeting 17 March 2016 Aisling Courtney.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
© 2016 Global Market Insights, Inc. USA. All Rights Reserved Fuel Cell Market size worth $25.5bn by 2024Low Power Wide Area Network.
221 Intestinal xenotransplantation from alpha 1,3-galactosyltransferase gene knockout and concurrent expression of membrane cofactor protein (MCP, CD46)
ODT - International Benchmarking
Fig 1 Trends in organ donors in the UK, 2000–10
Living Donor Transplants
Transforming the organ donation and transplantation pathway Making it Safer, Simpler, Supportive with the Hub Programme Anne Sheldon – Head of Referral.
Change of Outcomes in Pediatric Intestinal Failure: Use of Time-Series Analysis to Assess the Evolution of an Intestinal Rehabilitation Program  Carol.
Kidney Transplantation.
Donation after Brain-Stem Death DBD
Summary of the 2013 ERA-EDTA Registry Annual Report
Volume 61, Issue 3, Pages (September 2014)
Donation after Brain-Stem Death DBD
ABA Therapy Sydney Aspire Early Intervention Services
ABA Therapy Sydney - Aspire Early Intervention Services
The Organ Donation Process
In the name of God.
ODT Hub Programme Update National Organ Donation Committee Feb 2018 Jacki Newby Head of Referral and Offering 1.
The Organ Donation Process
Donation after circulatory death
Living Donation & Transplantation
Living Donor Transplants
S. Dupuis, J. -A. Amiel, M. Desgroseilliers, D. R. Williamson, Z
Saving Lives Is More Important Than Abstract Moral Concerns: Financial Incentives Should Be Used to Increase Organ Donation  Benjamin Hippen, MD, Lainie.
Midlands Organ Donation Services Team
Living Donor Transplants
Volume 61, Issue 3, Pages (September 2014)
ประกาศกระทรวงอุตสาหกรรม ฉบับที่ 5292 (พ.ศ. 2562)
Robert J. Porte, MD, PhD Professor of Surgery
Presentation transcript:

“NHSBT strategic vision meeting” Dr. Les Russell - October Tel +44 (0) Confidential to OrganOx Limited

Current status Confidential to OrganOx Limited 1.Increasing donor numbers envisaged next 5 years 2.Increasing ratio of DCD and ECD donors 3.Increasing use of Type II donors 4.Current static cold preservation techniques  Worse outcomes with prolonged cold storage  Increased damage with steatotic organs  No means of viability assessment 5.Decreasing use of “marginal” organs where transportation is an issue 6.Established retrieval and transplant practices in many countries

“Improving the supply and quality of organs for transplantation” “Making untransplantable livers transplantable” Confidential to OrganOx Limited : Copyright © OrganOx Limited

Designed by transplant surgeons for transplant surgeons Confidential to OrganOx Limited : Copyright © OrganOx Limited

Issues and trends through the next 5 years Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 6.Potential for interventions to improve outcomes

Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 1.Potential for interventions to improve outcomes Issues and trends through the next 5 years

Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 1.Potential for interventions to improve outcomes

Issues and trends through the next 5 years Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 1.Potential for interventions to improve outcomes

Issues and trends through the next 5 years Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 1.Potential for interventions to improve outcomes

Issues and trends through the next 5 years Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 1.Potential for interventions to improve outcomes

Issues and trends through the next 5 years Confidential to OrganOx Limited 1.Increased use of organs from elderly donors 2.Increased use of organs from further obese and ECD patients 3.Increasing pressure on transplant surgeons and teams to operate at unsocial hours 4.Greater logistical challenges 5.New technology needs justification 1.Potential for interventions to improve outcomes

Summary Confidential to OrganOx Limited 1.Desperate need to increase organ availability 2.Increasing use of marginal organs 3.Need for assessment of organ viability 4.Believe that NMP can make untransplantable organs transplantable  Increases organ availability  Improves patient outcomes and saves lives